S&P 500   3,627.90 (-0.21%)
DOW   29,858.62 (-0.62%)
QQQ   296.26 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   214.01 (+0.07%)
FB   275.82 (-0.40%)
GOOGL   1,765.70 (+0.10%)
AMZN   3,183.00 (+2.08%)
TSLA   570.65 (+2.75%)
NVDA   530.04 (+2.26%)
BABA   276.77 (-1.14%)
CGC   26.94 (-0.11%)
GE   10.50 (+0.48%)
MU   63.65 (-0.47%)
AMD   86.97 (+2.23%)
T   28.92 (-1.06%)
NIO   52.97 (-1.01%)
F   9.03 (-4.44%)
ACB   8.81 (-4.55%)
NFLX   484.84 (+0.41%)
GILD   59.54 (-1.18%)
BA   217.90 (-0.27%)
DIS   148.77 (-1.80%)
S&P 500   3,627.90 (-0.21%)
DOW   29,858.62 (-0.62%)
QQQ   296.26 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   214.01 (+0.07%)
FB   275.82 (-0.40%)
GOOGL   1,765.70 (+0.10%)
AMZN   3,183.00 (+2.08%)
TSLA   570.65 (+2.75%)
NVDA   530.04 (+2.26%)
BABA   276.77 (-1.14%)
CGC   26.94 (-0.11%)
GE   10.50 (+0.48%)
MU   63.65 (-0.47%)
AMD   86.97 (+2.23%)
T   28.92 (-1.06%)
NIO   52.97 (-1.01%)
F   9.03 (-4.44%)
ACB   8.81 (-4.55%)
NFLX   484.84 (+0.41%)
GILD   59.54 (-1.18%)
BA   217.90 (-0.27%)
DIS   148.77 (-1.80%)
S&P 500   3,627.90 (-0.21%)
DOW   29,858.62 (-0.62%)
QQQ   296.26 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   214.01 (+0.07%)
FB   275.82 (-0.40%)
GOOGL   1,765.70 (+0.10%)
AMZN   3,183.00 (+2.08%)
TSLA   570.65 (+2.75%)
NVDA   530.04 (+2.26%)
BABA   276.77 (-1.14%)
CGC   26.94 (-0.11%)
GE   10.50 (+0.48%)
MU   63.65 (-0.47%)
AMD   86.97 (+2.23%)
T   28.92 (-1.06%)
NIO   52.97 (-1.01%)
F   9.03 (-4.44%)
ACB   8.81 (-4.55%)
NFLX   484.84 (+0.41%)
GILD   59.54 (-1.18%)
BA   217.90 (-0.27%)
DIS   148.77 (-1.80%)
S&P 500   3,627.90 (-0.21%)
DOW   29,858.62 (-0.62%)
QQQ   296.26 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   214.01 (+0.07%)
FB   275.82 (-0.40%)
GOOGL   1,765.70 (+0.10%)
AMZN   3,183.00 (+2.08%)
TSLA   570.65 (+2.75%)
NVDA   530.04 (+2.26%)
BABA   276.77 (-1.14%)
CGC   26.94 (-0.11%)
GE   10.50 (+0.48%)
MU   63.65 (-0.47%)
AMD   86.97 (+2.23%)
T   28.92 (-1.06%)
NIO   52.97 (-1.01%)
F   9.03 (-4.44%)
ACB   8.81 (-4.55%)
NFLX   484.84 (+0.41%)
GILD   59.54 (-1.18%)
BA   217.90 (-0.27%)
DIS   148.77 (-1.80%)
Log in
NASDAQ:HTGM

HTG Molecular Diagnostics Stock Forecast, Price & News

$4.60
+0.16 (+3.60 %)
(As of 11/25/2020 02:57 PM ET)
Add
Compare
Today's Range
$4.30
Now: $4.60▼
$4.60
50-Day Range
$0.28
MA: $0.40▼
$4.71
52-Week Range
$3.78
Now: $4.60▼
$13.80
Volume4,885 shs
Average Volume203,100 shs
Market Capitalization$21.81 million
P/E RatioN/A
Dividend YieldN/A
Beta1.69
HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's marketed panels include HTG EdgeSeq oncology biomarker panel; HTG EdgeSeq immuno-oncology assay; HTG EdgeSeq DLBCL cell of origin assay; HTG EdgeSeq path assay; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq ALKPlus assay EU;HTG EdgeSeq precision immuno-oncology panel; HTG lung fusions assay; HTG autoimmune panel; and HTG mouse mRNA tumor response panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a governing agreement with QIAGEN Manchester Limited; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.
Read More
HTG Molecular Diagnostics logo

Beat the Market (BTM) Rank™

Analyst Opinion: 1.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.94 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HTGM
Previous Symbol
CUSIPN/A
CIK1169987
Webwww.htgmolecular.com
Phone877-289-2615
Employees108

Debt

Debt-to-Equity Ratio0.57
Current Ratio7.43
Quick Ratio7.14

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$19.20 million
Price / Sales1.14
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.41 per share
Price / Book11.22

Profitability

EPS (Most Recent Fiscal Year)($0.51)
Net Income$-19,300,000.00
Net Margins-141.02%
Return on Equity-85.82%
Return on Assets-44.87%

Miscellaneous

Outstanding Shares4,742,000
Market Cap$21.81 million
Next Earnings Date3/24/2021 (Estimated)
OptionableOptionable
$4.60
+0.16 (+3.60 %)
(As of 11/25/2020 02:57 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HTGM News and Ratings via Email

Sign-up to receive the latest news and ratings for HTGM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











HTG Molecular Diagnostics (NASDAQ:HTGM) Frequently Asked Questions

How has HTG Molecular Diagnostics' stock price been impacted by Coronavirus (COVID-19)?

HTG Molecular Diagnostics' stock was trading at $0.3942 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, HTGM shares have increased by 1,026.3% and is now trading at $4.44.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of HTG Molecular Diagnostics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HTG Molecular Diagnostics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for HTG Molecular Diagnostics.

What stocks does MarketBeat like better than HTG Molecular Diagnostics?

Wall Street analysts have given HTG Molecular Diagnostics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but HTG Molecular Diagnostics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is HTG Molecular Diagnostics' next earnings date?

HTG Molecular Diagnostics is scheduled to release its next quarterly earnings announcement on Wednesday, March 24th 2021.
View our earnings forecast for HTG Molecular Diagnostics.

How were HTG Molecular Diagnostics' earnings last quarter?

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) posted its quarterly earnings data on Tuesday, November, 10th. The medical research company reported ($0.07) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.06) by $0.01. HTG Molecular Diagnostics had a negative net margin of 141.02% and a negative return on equity of 85.82%.
View HTG Molecular Diagnostics' earnings history.

What price target have analysts set for HTGM?

4 brokerages have issued 1 year price targets for HTG Molecular Diagnostics' stock. Their forecasts range from $0.70 to $1.50. On average, they anticipate HTG Molecular Diagnostics' share price to reach $1.05 in the next twelve months. This suggests that the stock has a possible downside of 76.4%.
View analysts' price targets for HTG Molecular Diagnostics.

Are investors shorting HTG Molecular Diagnostics?

HTG Molecular Diagnostics saw a increase in short interest during the month of October. As of October 30th, there was short interest totaling 1,730,000 shares, an increase of 36.2% from the October 15th total of 1,270,000 shares. Based on an average daily trading volume, of 2,610,000 shares, the days-to-cover ratio is currently 0.7 days.
View HTG Molecular Diagnostics' Short Interest.

Who are some of HTG Molecular Diagnostics' key competitors?

Some companies that are related to HTG Molecular Diagnostics include Bionano Genomics (BNGO), EyePoint Pharmaceuticals (EYPT), Precipio (PRPO), Astrotech (ASTC), Scientific Industries (SCND), BioForce Nanosciences (BFNH), Pressure BioSciences (PBIO), Arrayit (ARYC), DiaSys (DYXC) and PositiveID (PSID).
View all competitors.

What other stocks do shareholders of HTG Molecular Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HTG Molecular Diagnostics investors own include Idera Pharmaceuticals (IDRA), Biocept (BIOC), Rigel Pharmaceuticals (RIGL), Heat Biologics (HTBX), MEI Pharma (MEIP), Zosano Pharma (ZSAN), Verastem (VSTM), Aurinia Pharmaceuticals (AUPH), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

Who are HTG Molecular Diagnostics' key executives?

HTG Molecular Diagnostics' management team includes the following people:
  • Mr. Timothy B. Johnson, Exec. Chairman (Age 59, Pay $212.35k)
  • Mr. John L. Lubniewski, Pres, CEO & Director (Age 56, Pay $384.87k)
  • Mr. Shaun D. McMeans, Sr. VP of Fin. & Admin., CFO, Sec. and Treasurer (Age 58, Pay $321.37k)
  • Ms. Laura Lee Godlewski, VP of Fin. & Principal Accounting Officer (Age 40)
  • Dr. Maureen T. Cronin, Sr. VP & Chief Scientific Officer (Age 67)

When did HTG Molecular Diagnostics IPO?

(HTGM) raised $50 million in an initial public offering on Wednesday, May 6th 2015. The company issued 3,600,000 shares at $13.00-$15.00 per share. Leerink Partners acted as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is HTG Molecular Diagnostics' stock symbol?

HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."

Who are HTG Molecular Diagnostics' major shareholders?

HTG Molecular Diagnostics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Nantahala Capital Management LLC (7.19%), Perkins Capital Management Inc. (3.43%), Cowen Prime Services LLC (2.00%), GSA Capital Partners LLP (1.71%), Bank Julius Baer & Co. Ltd Zurich (0.57%) and BlackRock Inc. (0.41%).
View institutional ownership trends for HTG Molecular Diagnostics.

Which major investors are selling HTG Molecular Diagnostics stock?

HTGM stock was sold by a variety of institutional investors in the last quarter, including Cowen Prime Services LLC, and BlackRock Inc..
View insider buying and selling activity for HTG Molecular Diagnostics.

Which major investors are buying HTG Molecular Diagnostics stock?

HTGM stock was purchased by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc., GSA Capital Partners LLP, Bank Julius Baer & Co. Ltd Zurich, and Nantahala Capital Management LLC.
View insider buying and selling activity for HTG Molecular Diagnostics.

How do I buy shares of HTG Molecular Diagnostics?

Shares of HTGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is HTG Molecular Diagnostics' stock price today?

One share of HTGM stock can currently be purchased for approximately $4.44.

How big of a company is HTG Molecular Diagnostics?

HTG Molecular Diagnostics has a market capitalization of $21.05 million and generates $19.20 million in revenue each year. The medical research company earns $-19,300,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. HTG Molecular Diagnostics employs 108 workers across the globe.

What is HTG Molecular Diagnostics' official website?

The official website for HTG Molecular Diagnostics is www.htgmolecular.com.

How can I contact HTG Molecular Diagnostics?

HTG Molecular Diagnostics' mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The medical research company can be reached via phone at 877-289-2615.

This page was last updated on 11/25/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.